Liposomal formulation of amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients.
about
Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).An update on pharmacotherapy for leishmaniasisLiposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea.[Treatment of diseases acquired abroad].Intraspecies differences in natural susceptibility to amphotericine B of clinical isolates of Leishmania subgenus Viannia.Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome and AmBisome in murine cutaneous leishmaniasis
P2860
Liposomal formulation of amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Liposomal formulation of ampho ...... asis in HIV-negative patients.
@en
Liposomal formulation of ampho ...... asis in HIV-negative patients.
@nl
type
label
Liposomal formulation of ampho ...... asis in HIV-negative patients.
@en
Liposomal formulation of ampho ...... asis in HIV-negative patients.
@nl
prefLabel
Liposomal formulation of ampho ...... asis in HIV-negative patients.
@en
Liposomal formulation of ampho ...... asis in HIV-negative patients.
@nl
P2093
P2860
P356
P1476
Liposomal formulation of ampho ...... asis in HIV-negative patients.
@en
P2093
Antonio Carlos Nicodemo
Carolina Rocio
Raphael A Camargo
Valdir Sabbaga Amato
P2860
P304
P356
10.1093/TRSTMH/TRU011
P577
2014-03-01T00:00:00Z